7Baggers

We provide you with 20 years of free, institutional-grade data for ABCL stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ABCL. Explore the full financial landscape of ABCL stock.

Reported DateCIKTickerType
2025-08-071703057ABCL10-QUrl
2025-05-081703057ABCL10-QUrl
2025-02-271703057ABCL10-KUrl
2024-11-041703057ABCL10-QUrl
2024-08-061703057ABCL10-QUrl
2024-05-071703057ABCL10-QUrl
2024-02-201703057ABCL10-KUrl
2023-11-021703057ABCL10-QUrl
2023-08-031703057ABCL10-QUrl
2023-05-041703057ABCL10-QUrl
2023-02-211703057ABCL10-KUrl
2022-11-081703057ABCL10-QUrl
2022-08-091703057ABCL10-QUrl
2022-05-101703057ABCL10-QUrl
2022-02-251703057ABCL10-KUrl
2021-11-101703057ABCL10-QUrl
2021-08-131703057ABCL10-QUrl
2021-06-101703057ABCLS-1Url
2021-05-141703057ABCL10-QUrl
2021-03-301703057ABCL10-KUrl
2020-11-201703057ABCLS-1Url

AbCellera Biologics Inc
(NASDAQ:ABCL) 

ABCL stock logo

AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, AI-powered drug discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. As of December 31, 2020, the company had 103 discovery programs that are e...

Founded: 2012
Full Time Employees: 174
CEO: Carl Hansen  
Sector: Healthcare
Industry: Biotechnology

Share this website to your friends
The information provided in this report about ABCL stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.